- Home
- ACIU vs CDXS Comparison
ACIU vs CDXS Comparison
Compare ACIU & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- CDXS
- Stock Information
- Founded
- ACIU 2003
- CDXS 2002
- Country
- ACIU Switzerland
- CDXS United States
- Employees
- ACIU N/A
- CDXS N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- ACIU Health Care
- CDXS Industrials
- Exchange
- ACIU Nasdaq
- CDXS Nasdaq
- Market Cap
- ACIU 213.3M
- CDXS 216.6M
- IPO Year
- ACIU 2016
- CDXS 2010
- Fundamental
- Price
- ACIU $3.36
- CDXS $1.71
- Analyst Decision
- ACIU Strong Buy
- CDXS Buy
- Analyst Count
- ACIU 2
- CDXS 1
- Target Price
- ACIU $10.00
- CDXS $11.00
- AVG Volume (30 Days)
- ACIU 417.2K
- CDXS 672.2K
- Earning Date
- ACIU 11-04-2025
- CDXS 11-06-2025
- Dividend Yield
- ACIU N/A
- CDXS N/A
- EPS Growth
- ACIU N/A
- CDXS N/A
- EPS
- ACIU N/A
- CDXS N/A
- Revenue
- ACIU $5,482,957.00
- CDXS $57,164,000.00
- Revenue This Year
- ACIU N/A
- CDXS $12.88
- Revenue Next Year
- ACIU $1,022.98
- CDXS $21.64
- P/E Ratio
- ACIU N/A
- CDXS N/A
- Revenue Growth
- ACIU N/A
- CDXS N/A
- 52 Week Low
- ACIU $1.43
- CDXS $1.90
- 52 Week High
- ACIU $4.00
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- ACIU 53.82
- CDXS 21.59
- Support Level
- ACIU $3.20
- CDXS $2.52
- Resistance Level
- ACIU $3.70
- CDXS $2.80
- Average True Range (ATR)
- ACIU 0.40
- CDXS 0.14
- MACD
- ACIU -0.01
- CDXS -0.08
- Stochastic Oscillator
- ACIU 53.28
- CDXS 8.25
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.